Cloverleaf Bio
PrivateLast Round
Seed
Sep 8, 2026
Total Funding Raised
$33.76M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Cloverleaf Bio operates in Healthcare & Life Sciences and is based in New Haven, Connecticut. Its latest recorded funding round was a Seed round in September 2026.
Cloverleaf Bio is a biotechnology company developing a novel class of engineered tRNA-based therapeutics for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cloverleaf Bio Comparables
Compare Cloverleaf Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 81% | |
| Shape Therapeutics | 78% | |
| Tevard Biosciences | 78% |
For institutional investors. Book with your work email.
Cloverleaf Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 8, 2026 | ||||
| Grant | Sep 15, 2025 | ||||
| Grant | Jun 23, 2025 | ||||
| Accelerator | Oct 30, 2024 |
For institutional investors. Book with your work email.
Cloverleaf Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Threshold Ventures | Seed |
| 4BIO Capital | Seed |
| AbbVie Ventures | Seed |
| BrightEdge | Seed |
| Draper Associates | Seed |
| Boehringer Ingelheim Venture Fund | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Open roles increased to 4, 80% of headcount.
- Sep 21, 2026
Open roles increased to 3, 60% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 15, 2026
Cloverleaf Bio is developing therapies based on transfer RNA, or tRNA, designed to disrupt protein production in cancer cells while limiting damage to healthy tissue; funding supports early-stage human testing of a potential liver cancer treatment and preclinical development of a colorectal cancer therapy in Connecticut.
- receives_financingSep 8, 2026
On Sep 8th '26, Cloverleaf Bio raises a $33M Seed round led by 4BIO Capital, with participation from AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge, to advance cancer programs toward clinical and preclinical development in Connecticut.
For institutional investors. Book with your work email.
Cloverleaf Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cloverleaf Bio's valuation, stock price, and market status.
Is Cloverleaf Bio a public or private company?
Cloverleaf Bio is a private company.
What is the current stock price of Cloverleaf Bio?
Cloverleaf Bio is a private company, so its shares have no public market price. Caplight tracks Cloverleaf Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cloverleaf Bio worth (valuation)?
Valuation information for Cloverleaf Bio is not publicly available.
Can I buy Cloverleaf Bio stock?
Cloverleaf Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cloverleaf Bio's last funding round?
Cloverleaf Bio's most recent funding round was Seed on September 8, 2026.
Who are the main investors in Cloverleaf Bio?
Key investors in Cloverleaf Bio include 4BIO Capital.
Will Cloverleaf Bio IPO soon?
No public IPO plans have been announced for Cloverleaf Bio.
How can I track Cloverleaf Bio secondary market activity?
Caplight tracks bids, offers, and trades in Cloverleaf Bio's shares on secondary markets.